Boehringer Ingelheim

INGELHEIM, Germany & RIDGEFIELD, Conn., May 21, 2026 Boehringer Ingelheim has unveiled significant new oncology data at the 2026...

INGELHEIM, Germany and WALTHAM, Mass., May 12, 2026 Boehringer Ingelheim has entered into a global licensing agreement with Immunitas...

INGELHEIM, GERMANY, April 28, 2026 Boehringer Ingelheim has announced positive Phase III results for its investigational dual agonist survodutide,...

Ingelheim, Germany, April 20, 2026 Boehringer Ingelheim has announced a major strategic expansion of its computational innovation capabilities with...

Ingelheim, Germany & Shanghai, China | April 15, 2026 Boehringer Ingelheim and Zai Lab have announced a strategic clinical...

INGELHEIM, GERMANY, April 13, 2026 Boehringer Ingelheim has introduced LENZELTA®, a new veterinary vaccine designed to prevent mastitis in...

LYON, France, April 09, 2026 Boehringer Ingelheim has announced its continued support for Ecuador’s national effort to eliminate dog-mediated...

INGELHEIM, Germany, April 9, 2026 Boehringer Ingelheim has announced a strategic clinical trial collaboration with BioNTech to evaluate a...

Ingelheim, Germany | January 29, 2026 — Boehringer Ingelheim announced positive results from a 12-week Phase II clinical trial...

Ingelheim, Germany, November 28, 2025 Boehringer Ingelheim has announced a strategic leadership expansion with the appointment of Harsha Deshmukh...